Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Antibodies produced by a single clone of cells.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Antibodies reactive with HIV ANTIGENS.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Sites on an antigen that interact with specific antibodies.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Neoplasms containing cyst-like formations or producing mucin or serum.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Immunoglobulins produced in a response to FUNGAL ANTIGENS.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Tumors or cancer of the SKIN.
A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.
Antibodies that can catalyze a wide variety of chemical reactions. They are characterized by high substrate specificity and share many mechanistic features with enzymes.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Tumors or cancers of the KIDNEY.
A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
Tumors or cancer of the LUNG.
Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Tumors or cancer of the THYROID GLAND.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Established cell cultures that have the potential to propagate indefinitely.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Substances that are recognized by the immune system and induce an immune reaction.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the LIVER.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
DNA present in neoplastic tissue.
Substances elaborated by bacteria that have antigenic activity.
Proteins prepared by recombinant DNA technology.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A general term for various neoplastic diseases of the lymphoid tissue.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Tumors or cancer of the PAROTID GLAND.
A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.
The sum of the weight of all the atoms in a molecule.
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Substances elaborated by viruses that have antigenic activity.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Elements of limited time intervals, contributing to particular results or situations.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Tumors or cancer of the ENDOCRINE GLANDS.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the COLON.
Tumors or cancer of the EYE.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.
Tumors or cancer of the NOSE.
EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.
Tumors or cancer of the SALIVARY GLANDS.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.
A benign epithelial tumor with a glandular organization.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumors or cancer of the UTERUS.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
Techniques for removal by adsorption and subsequent elution of a specific antibody or antigen using an immunosorbent containing the homologous antigen or antibody.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Antibodies obtained from a single clone of cells grown in mice or rats.
The phenomenon of immense variability characteristic of ANTIBODIES. It enables the IMMUNE SYSTEM to react specifically against the essentially unlimited kinds of ANTIGENS it encounters. Antibody diversity is accounted for by three main theories: (1) the Germ Line Theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; (2) the Somatic Mutation Theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and (3) the Gene Rearrangement Theory, which holds that antibody diversity is generated by the rearrangement of IMMUNOGLOBULIN VARIABLE REGION gene segments during the differentiation of the ANTIBODY-PRODUCING CELLS.
Tumors or cancer located in bone tissue or specific BONES.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the INTESTINES.
A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.
An encapsulated lymphatic organ through which venous blood filters.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
A malignant epithelial tumor with a glandular organization.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Tumors or cancer of the human BREAST.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Tumors or cancer of the BILE DUCTS.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
Tumors or cancer of the SPLEEN.
Neoplasms composed of more than one type of neoplastic tissue.
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk.
Tumors or cancer of the MANDIBLE.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Antibodies specific to INSULIN.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
Field of chemistry that pertains to immunological phenomena and the study of chemical reactions related to antigen stimulation of tissues. It includes physicochemical interactions between antigens and antibodies.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Tumors or cancer of the STOMACH.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Cancer or tumors of the MAXILLA or upper jaw.
Diagnostic procedures involving immunoglobulin reactions.
Glycoproteins found on the membrane or surface of cells.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Tumors or cancer of the anal gland.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
The rate dynamics in chemical or physical systems.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.
Polysaccharides found in bacteria and in capsules thereof.
A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.

Immune responses to all ErbB family receptors detectable in serum of cancer patients. (1/1721)

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.  (+info)

Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. (2/1721)

p53 alterations are considered to be predictive of poor prognosis in hepatocellular carcinoma (HCC) and may induce a humoral response. Anti-p53 serum antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using purified recombinant human p53 on 130 European HCC patients before treatment and during the clinical course of the disease. p53 immunohistochemistry was performed on tumours from the 52 patients who underwent surgery, and DNA sequencing analysis was initiated when circulating anti-p53 antibodies were detected. Nine (7%) HCC patients had anti-p53 serum antibodies before treatment. During a mean period of 30 months of follow-up, all the negative patients remained negative, even when recurrence was observed. Of the nine positive patients, eight were still positive 12-30 months after surgery. The presence of anti-p53 serum antibodies was correlated neither with mutation of the p53 gene nor the serum alpha-fetoprotein levels and clinicopathological characteristics of the tumours. However, a greater incidence of vascular invasion and accumulation of p53 protein were observed in the tumours of these patients (P<0.03 and P<0.01 respectively) as well as a better survival rate without recurrence (P = 0.05). In conclusion, as was recently shown in pancreatic cancer, anti-p53 serum antibodies may constitute a marker of relative 'good prognosis' in a subgroup of patients exhibiting one or several markers traditionally thought to be of bad prognosis.  (+info)

Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library. (3/1721)

To identify the epitope of the melanoma-associated chondroitin sulfate proteoglycan (MCSP) recognized by the monoclonal antibody (mAb) 763.74, we first expressed random DNA fragments obtained from the complete coding sequence of the MCSP core glycoproteins in phages and selected without success for binders to the murine mAb 763.74. We then used a library of random heptapeptides displayed at the surface of the filamentous M13 phage as fusion protein to the NH2-terminal portion of the minor coat protein III. After three rounds of selection on the bound mAb, several phages displaying related binding peptides were identified, yielding the consensus sequence Val-His-Leu-Asn-Tyr-Glu-His. Competitive ELISA experiments showed that this peptide can be specifically prevented from binding to mAb 763.74 by an anti-idiotypic MK2-23 mouse:human chimeric mAb and by A375 melanoma cells expressing the antigen MCSP. We screened the amino acid sequence of the MCSP molecule for a region of homology to the consensus sequence and found that the amino acid sequence Val-His-Ile-Asn-Ala-His spanning positions 289 and 294 has high homology. Synthetic linear peptides corresponding to the consensus sequence as well as to the MCSP-derived epitope inhibit the binding of mAb 763.74 to the phages displaying the consensus amino acid sequence. Finally, the biotinylated consensus peptide absorbed to streptavidin-microtiter plates can be used for the detection of mAb 763.74 in human serum. These results show clearly that the MCSP epitope defined by mAb 763.74 has been identified.  (+info)

A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. (4/1721)

In this study we performed N-terminal sequence analysis of gp20, a 20 kDa sialoglycoprotein on the human sperm surface previously identified by radiolabelling of the sialic acid residues of sperm surface. We found 100% identity with the N-terminus of CD52, an antigen expressed on almost all human leukocytes. We also show that, like CD52, gp20 behaves as a glycosylphosphatidylinositol (GPI)-anchored protein and that anti-gp20 antiserum reacts with an antigen on leukocytes of the same molecular weight as CD52. Using CAMPATH-1, the monoclonal antibody against CD52, in fluorescent staining of capacitated spermatozoa, Western blot analysis and the zona-free hamster egg penetration test, we found that the effect of this antibody was different from that of our anti-gp20. Western blot analysis revealed a well-defined 20 kDa band with anti-gp20, whereas a 14-20 kDa band was detected with CAMPATH-1. Anti-gp20 stained the equatorial region of the sperm head, whereas CAMPATH-1 stained the tail in immunofluorescence analysis of capacitated spermatozoa. A dose-dependent inhibitory effect was seen with CAMPATH-1, similar to that previously detected with anti-gp20, in a zona-free hamster egg penetration test. However, with CAMPATH-1 agglutination of motile spermatozoa was detected, and this was not present with anti-gp20. This suggests that the epitopes recognized by the two antibodies are different.  (+info)

Adoptive immunotherapy of a Gross virus producing lymphoma and a methylcholanthrene-induced fibrosarcoma in tolerant rats. (5/1721)

Immunological tolerance to Gross virus-specific transplantation antigens in rats given neonatae transfer of donor lymphoid cells beneath the kidney capsule of syngeneic recipient rats. Immune or normal donor cells invariably developed a cell-mediated immune reaction in kidneys of GV-tolerant recipients, presumably against GV antigens present on the surface of recipient lymphoid cells in the kidney. Spleen and lymph node cells from tolerant rats failed to develop a reaction in tolerant recipients, but developed a strong reaction to histoincompatible antigens in the kidneys of semisyngeneic tolerant rats. The immunologically tolerant state in the rats could be broken by adoptive transfer of spleen and lymph node cells from syngeneic rats immunized with GV-induced lymphoma cells. Immunotherapy of a GV-induced and also a GV-infected methylcholanthrene-induced fibrosarcoma growing in tolerant rats was successful when immune spleen and lymph node cells were administered i.p. 3 days after s.c. inoculation of 2 X 10(7) tumor cells in the case of the lymphoma, and 1 day after inoculation of 5 X 10(6) tumor cells in the case of the fibrosarcoma.  (+info)

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. (6/1721)

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is directed against the Lewis-Y antigen, which is expressed on 75% of all breast cancers but is limited in expression on normal tissues. Preclinical xenograft models demonstrated significant antitumor activity, including cures. A randomized phase II design was chosen to estimate the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin. PATIENTS AND METHODS: Patients with measurable metastatic breast cancer and immunohistochemical evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m2 IV over 24 hours or doxorubicin 60 mg/m2 every 3 weeks. Patients were stratified on the basis of prior doxorubicin exposure, visceral disease, and institution. Cross-over to the opposite treatment arm was allowed with progressive or persistently stable disease. RESULTS: Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable. There was one partial response (7%) in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses (44%) in nine assessable patients receiving doxorubicin. No patient experienced a clinically significant hypersensitivity reaction. The toxicities were significantly different between the two treatment groups, with the BR96-doxorubicin conjugate group having limited hematologic toxicity, whereas gastrointestinal toxicities, including marked serum amylase and lipase elevations, nausea, and vomiting with gastritis, were prominent. CONCLUSION: The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer. The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites.  (+info)

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. (7/1721)

PURPOSE: In patients undergoing cytokine therapy, systemically applied interleukin-2 (IL-2) and/or interferon-alpha (IFN-alpha) have been reported to induce thyroid dysfunction as well as thyroid autoantibodies. We analyzed the correlation of thyroid autoimmunity with HLA phenotype, various other autoimmune parameters, and patient survival. PATIENTS AND METHODS: For this purpose, antithyroglobulin autoantibodies, antimicrosomal thyroid autoantibodies, thyroglobulin receptor autoantibodies, thyroid dysfunction, and multiple clinical parameters were determined in 329 unselected patients with metastatic renal cell cancer before and after systemic IL-2 and IFN-alpha2 therapy. For statistical analysis, we used both univariate and multivariate Cox proportional hazards models and the two-tailed Fisher's exact test. RESULTS: Antithyroglobulin autoantibodies and antimicrosomal thyroid autoantibodies were detected in 60 patients (18%); positive autoantibody titers of various other autoimmune parameters were statistically unrelated. The presence of thyroid autoantibodies was correlated with prolonged survival (P<.0001). There was a statistically significant difference in frequencies of HLA-Cw7 expression between thyroid autoantibody-positive and -negative patients (P< or =.05), and the Cw7 expression was associated with prolonged overall survival (P = .009). CONCLUSION: The evaluation of thyroid autoantibodies during cytokine therapy could be a useful prognostic marker for patients with renal cell carcinoma who benefit from cytokine treatment. IL-2- and IFN-alpha2-induced tumor control and prolonged survival may require breaking of immunologic tolerance against self-antigens.  (+info)

Prognostic value of p53 genetic changes in colorectal cancer. (8/1721)

PURPOSE: To explore whether there is a linkage between different mutations in the p53 gene in primary colorectal cancer and the risk of death from colorectal cancer in a large group of patients with long follow-up. We also compared a complementary DNA-based sequencing method and an immunohistochemical (IHC) method for detecting p53 protein overexpression in colorectal cancer. MATERIALS AND METHODS: The entire coding region of the p53 gene was sequenced in 191 frozen tumor samples collected from January 1988 to November 1992. RNA was extracted and synthesized to cDNA. p53 was amplified by the polymerase chain reaction, and the DO-7 monoclonal antibody was used in the IHC assessments. RESULTS: Mutations were detected in 99 samples (52%) from 189 patients. There was a significant relationship between the p53 mutational status and the cancer-specific survival time, with shorter survival time for patients who had p53 mutations than for those who did not (P = .01, log-rank test). Mutations outside the evolutionarily conserved regions were associated with the worst prognosis. Multivariate analysis showed that the presence of p53 mutations was an independent prognostic factor (relative hazard, 1.7, P = .03). There was no significant relationship between overexpression of p53 protein, as determined by IHC analysis, and cancer-specific survival. CONCLUSION: Mutational analyses of the p53 gene, using cDNA sequencing in colorectal cancer, provide useful prognostic information. In addition, cDNA sequencing gives better prognostic information than IHC assessment of p53 protein overexpression.  (+info)

This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced
Open label multicenter, two-step, non-randomized (pilot) study to analyze the safety of 4 cycles of 3-day 40mg/m2 oral fludarabine with simultaneous thrice weekly application of 30mg alemtuzumab s.c. in patients with B-CLL disease in 1st and 2nd relapse after any primary treatment or with disease refractory to any therapy in 1st or 2nd line (including Fludarabine, ). This regimen is preceded by an escalation phase with 3-10-30 mg of alemtuzumab s.c.. After the first phase (completed treatment of 7 patients) an interim analysis of safety and efficacy will be performed. In case of a sufficient risk benefit assessment followed by the enrollment of further 21 patients. Final analysis of safety and preliminary efficacy will be based on all patients enrolled. ...
The screening of cDNA expression libraries derived from human tumors with autologous antibody (SEREX) is a powerful method for defining the structure of tumor antigens recognized by the humoral immune system. Sixty-five distinct antigens (NY-REN-1 to NY-REN-65) reactive with autologous IgG were iden …
Every participant had received active treatment; there was no placebo. Participants who qualified were randomly assigned to treatment with either alemtuzumab or SC interferon beta-1a at a 2:1 ratio (that is, 2 given alemtuzumab for every 1 given interferon beta-1a). Alemtuzumab was administered in two annual courses, once at the beginning of the study and again 1 year later. Interferon beta-1a was self-injected 3 times per week for 2 years. All participants were required to return to their study site every 3 months for neurologic assessment. In addition, safety-related laboratory tests were performed at least monthly. Participation in this study ended 2 years after the start of treatment for each participant. Additionally, participants who received alemtuzumab might be followed in CAMMS03409 (NCT00930553) an extension study for safety and efficacy assessments. Participants who received interferon beta-1a and completed 2 years on study might be eligible to receive alemtuzumab on the extension ...
Alemtuzumab is used in the treatment of blood cancer (chronic lymphocytic leukemia),multiple sclerosis (ms).get complete information about alemtuzumab including usage, side effects, drug interaction, expert advice along with medicines associated with alemtuzumab at
In an analysis of in periods of yore unpublished position III data, U.K. researchers broadcast a oversized, speedy repopulation of a subset of B waste times without vigorous T-cell contribution in patients with multiple sclerosis (MS) enquired with alemtuzumab (Lemtrada), which rule have authored an environment for ancillary autoimmune sickness.. Pumping lymphocyte reconstitution subject-matter from the cardinal Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I and II (CARE-MS I and II) readings, Klaus Schmierer, PhD, FRCP, of Ruler Mary University of London, and joins found that alemtuzumab depleted CD4 T foot-draggings by more than 95%, off regulatory areas and CD8 T cells, which corpsed affectionately deeper testimonial levels globally in the trials. Although the fussy also initially depleted CD19 B corrals by more than 85%, new B apartments distended by 180% and transmuted to season B chambers as a remainder straightaway. These interchanges were associated with the armada ...
CAMPATH (Alemtuzumab) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Id like to share with you that I received alemtuzumab (Campath trade name) in the hospital 26.04. - 30/04/2011 under the program CARE MS II extension study. Side effects of alemtuzumab infusions continue after I get tired, the most troublesome ...
Mouse monoclonal CD13 antibody [CC81] validated for Flow Cyt and tested in Cow. Immunogen corresponding to tissue, cells or virus
Mouse monoclonal WC1 antibody [CC101] validated for IP, IHC, Flow Cyt and tested in Cow and Pig. Immunogen corresponding to tissue, cells or virus
CD1w3 antibody [CC43] for FACS, IP. Anti-CD1w3 mAb (GTX42307) is tested in Goat, Sheep, Bovine, Sheep samples. 100% Ab-Assurance.
Wc1 antibody [CC15] (FITC) (CD163 molecule-like 1) for FACS. Anti-Wc1 mAb (GTX43329) is tested in Goat, Sheep, Bovine, Sheep samples. 100% Ab-Assurance.
1AD9: VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs.
I was in the CAMMS323 trial and I received Campath (although I still do not know the dosage). I was only diagnosed with RRMS for one year and 2 months before going into the trial. I am currently at month ...
Learn ways to provide support to your loved ones with relapsing MS, hear advice from other Care Partners, and see what Care Partners mean to MS patients.
引用Abcams Anti-p38抗体[M138] (ab31828)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
BACKGROUND: Calcineurin inhibitors (CNIs) reduce short-term kidney transplant failure, but might contribute to transplant failure in the long-term. The role of alemtuzumab (a potent lymphocyte-depleting antibody) as an induction treatment followed by an early reduction in CNI and mycophenolate exposure and steroid avoidance, after kidney transplantation is uncertain. We aimed to assess the efficacy and safety of alemtuzumab-based induction treatment compared with basiliximab-based induction treatment in patients receiving kidney transplants. METHODS: For this randomised trial, we enrolled patients aged 18 years and older who were scheduled to receive a kidney transplant in the next 24 h from 18 transplant centres in the UK. Using minimised randomisation, we randomly assigned patients (1:1; minimised for age, sex, and immunological risk) to either alemtuzumab-based induction treatment (ie, alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids) or basiliximab-based induction
A 64-year-old woman, with unremarkable previous medical history, was diagnosed with T cell prolymphocytic leukemia in 2006. She received alemtuzumab (30 mg subcutaneously thrice weekly) as first line chemotherapy; combined therapy of valaciclovir and trimethoprim-sulfamethoxazole, for anti-infective prophylaxis, was initiated simultaneously. Before institution of alemtuzumab therapy, full blood cell count disclosed the following: hemoglobin 12.7 g/dL, white blood cell count 88×109/L (absolute neutrophil count: 8.5×109/L, lymphocyte: 79.5×109/L, platelets: 400,000/mm3). Two days after the 9th alemtuzumab injection, the patient exhibited an asymptomatic reactivation of cytomegalovirus (CMV) infection; she was given valganciclovir therapy for 21 days.. Three days after the 16th alemtuzumab injection, she was admitted with a 2-day history of abdominal pain. On admission, the patient was febrile (38°5C); physical examination showed a tenderness in the appendicular area. Laboratory findings ...
The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal antibody alemtuzumab for high-risk chronic lymphocytic leukemia, defined as at least 1 of the following: unmutated immunoglobulin heavy chain genes, deletion 17p or 11q, or trisomy 12. Fit patients were randomized to receive either 6 28-day cycles of oral FC chemotherapy (days 1 through 3: fludarabine 40 mg/m(2) per day and cyclophosphamide 250 mg/m(2) per day: n = 139) or FC plus subcutaneous alemtuzumab 30 mg day 1 (FCA, n = 133). FCA prolonged the primary end point, progression-free survival (3-year progression-free survival 53 vs 37%, P = .01), but not the secondary end point, overall survival (OS). However, a post hoc analysis showed that FCA increased OS in patients younger than 65 years (3-year OS 85% vs 76%, P = .035). FCA also increased the overall response rate (88 vs 78%, P = .036), and the bone marrow minimal residual ...
Recent clinical outcomes and subsequent approvals of anti-CTLA-4 and anti-PD-1 checkpoint blockade antibodies, which mitigate inhibitory signaling that decreases antitumor T cell responses, have ignited extraordinarily broad efforts to develop the potential of cancer immunotherapy (Pardoll, 2012; Topalian et al., 2015). Unlike strategies that typically elicit antitumor responses of limited duration and nearly inevitable treatment resistance, immunotherapeutics can achieve durable and long-lasting antitumor responses in a minority of patients with advanced disease (Sharma and Allison, 2015). To build upon this success, combination immunotherapies are a next logical step (Gajewski et al., 2013; Spranger and Gajewski, 2013).. One such approach combines a tumor-specific antibody to drive antibody-dependent cell-mediated cytotoxicity (ADCC) through neutrophil- and eosinophil-mediated attack and an extended serum half-life IL-2 fusion to activate CD8+ T cells and NK cells. However, this strategy is ...
A radioimmunoconjugate of the humanized monoclonal antibody CC49 labeled with iodine I 131. Iodine I 131 monoclonal antibody CC49 delivers beta and gamma radiation-emitting I 131 radionuclide specifically to tumor cells that express tumor-associated glycoprotein (TAG)-72, allowing localization of TAG-72-expressing tumor cells with radioimaging devices in diagnostic applications or resulting in specific TAG-72-expressing tumor cell radiocytotoxicity in therapeutic applications. Monoclonal antibody CC49 binds to TAG-72, a pancarcinoma antigen, with high affinity.. ...
Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between 1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant delays in immune reconstitution. Here we report |20 years of follow-up data from this unique cohort. Surviving alemtuzumab recipients were age, sex and disease duration matched with RA controls. Updated mortality and morbidity data were collected for alemtuzumab recipients. For both groups antigenic responses were assessed following influenza, Pneumovax II and combined diphtheria/tetanus/poliovirus vaccines. Circulating cytokines and lymphocyte subsets were also quantified. Of 16 surviving alemtuzumab recipients, 13 were recruited: 9 recipients underwent a full clinical assessment and 4 had case notes review only. Since our last review 10 patients had died from causes of death consistent with long-standing RA, and no suggestion of compromised immune function. Compared with controls the alemtuzumab cohort had
Nishioka, K; Irie, R F.; Kawana, T; and Takeuchi, S, Immunological studies on mouse mammary tumors. Iii. Surface antigens reacting with tumor-specific antibodies in immune adherence. (1969). Subject Strain Bibliography 1969. 1210 ...
In a prospective phase III study in Germany,[155] patients were randomly allocated either no treatment or alemtuzumab 30 mg intravenously three times a week for 12 weeks, beginning a median of 67 days after the last dose of induction chemotherapy (fludarabine with or without cyclophosphamide). Although recruitment to this trial was halted at 21 patients because of severe infections in the alemtuzumab group, those allocated alemtuzumab had significantly longer progression-free survival than those assigned no treatment. Using a very sensitive PCR-based assay with sequence-specific primers to detect minimal residual disease, five of six patients tested became negative for minimal residual disease. Findings of a phase II study156 of alemtuzumab given in doses of 10 mg subcutaneously three times a week for 6 weeks, beginning not less than 8 weeks after discontinuation of fludarabine induction chemotherapy, proved that this regimen was safe and able to turn partial remissions into complete remissions. ...
Alemtuzumab (marketed as Campath or Campath-1H) is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL) and T-cell lymphoma. Alemtuzumab targets CD52, a protein present on
1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol 2005; 23: 1147-1157. 2. Klener P, Klener P jr. Nová protinádorová léčiva a léčebné strategie v onkologii Grada Publishing a.s. Praha, 2010. 3. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Natur Rev 2010; 10: 317-327. 4. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkinęs lymphoma. Drugs 2007; 67: 333-350. 5. Belada D. Monoklonální protilátky v léčbě lymfomů. Remedia 2008; 6: 416.423 6. Castillo J, Winer E, Quinsberry O. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36: 755-768. 7. Wierda WG, Kipps TJ, Keatimg MJ, et al. Self-administered. subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011; 117: 116-124. 8. Khubchandani S, Czuczman MS, Hernandes-Ilizalituri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of ...
INTRODUCTION: Alemtuzumab is a humanised anti-CD52 mAb which has recently been licensed for the treatment of relapsing multiple sclerosis in Europe. AREAS COVERED: The efficacy and safety of alemtuzumab from open label, Phase II and Phase III trials is reported. EXPERT OPINION: Alemtuzumab causes rapid and profound complement mediated lysis of circulating lymphocytes and allows beneficial modulation of the immune system during a subsequent reconstitution phase. Clinical trials have demonstrated superior efficacy against an active comparator, with reduction in annualised relapse rates and sustained accumulation of disability at 3 years and sustained efficacy at 5 years. The main adverse effects are mild to moderate infusion reactions, an increased incidence of mild to moderate infections and autoimmune adverse events. Thyroid disorders are the most common form of autoimmune adverse events, occurring in approximately one third of patients. Overt Graves hyperthyroidism represents approximately ...
The right thing to do is to is to figure out how to prevent MS in future generations. Forget the DMTs and trials into progressive MS; lets just start from a clean slate. Its unfortunate that we have MS but lets bite the bullet and shift our focus on newborns. Lets make them vitamin D replete. Let us be the last generation to have lived and died with MS. Weve had our moment. Lets accept our fate and live with it rather than drugging ourselves with crap our bodies cant handle. The only reason a MSer will run the risk of taking alemtuzumab is because of desperation. Desperate people are always living in danger. MS can be prevented but its dangerous to think that modern toxins will, somehow, cure it ...
Patient Guide Important information for patients starting therapy with LEMTRADA (alemtuzumab) This medicinal product is subject to additional monitoring. This will allow quick identification of new safety
This is a study designed to test whether giving alemtuzumab on a maintenance schedule will prolong the time until the patient requires chemotherapy.
View: Main AbID Search Nested - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;}tr{ -webkit-transition: all .35s ease-in-out; /* Safari 3.1 to 6.0 */ transition: all .35s ease-in-out; } /* ----------------------------------------- */ /* View: Main AbID Search Nested - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;} /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: ProductsInAntibodyTbl - start */ /* ----------------------------------------- */ a.productappearance{ display:inline-block; font-size:80%; padding:3px; background:gray; color:white!important; ...
Unfortunately, there is no cure for multiple sclerosis, however, there are several different options for treating the condition. Find out about specialists who treat the disease and forms of treatment... ...
Alemtuzumab is a highly effective drug for multiple sclerosis, approved in more than 60 countries and used by more than 12,000 patients worldwide.
Lemtrada (alemtuzumab) - IV infusion given over the course of 5 consecutive days, followed 1 year later with a 3 day consecutive course
Lemtrada (alemtuzumab) - IV infusion given over the course of 5 consecutive days, followed 1 year later with a 3 day consecutive course
Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) offers a potential cure for patients with myelodysplastic syndrome (MDS) who are ineligible for standard-intensity regimens. Previously published data from our institution suggest excellent outcomes at 1 yr using a uniform fludarabine, busulfan, and alemtuzumab-based regimen. Here we report long-term follow-up of 192 patients with MDS and acute myelogenous leukemia (AML) secondary to MDS (MDS-AML) transplanted with this protocol, using sibling (n = 45) or matched unrelated (n = 147) donors. The median age of the cohort was 57 yr (range, 21 to 72 yr), and median follow-up was 4.5 yr (range, 0.1 to 10.6 yr). The 5-yr overall survival (OS), event-free survival, and nonrelapse mortality were 44%, 33%, and 26% respectively. The incidence of de novo chronic graft-versus-host disease (GVHD) was low at 19%, illustrating the efficacy of alemtuzumab for GVHD prophylaxis. Conversely, the 5-yr relapse rate ...
Link to Pubmed [PMID] - 9309422. Hybridoma 1997 Aug;16(4):317-24. We report here the first amino acid sequence of an anti-Tn monoclonal antibody raised against human breast cancer cells and show that a single chain Fv fragment of this IgM retains the Tn-binding specificity as defined by functional assays with asialo-OSM and membrane extracts from MCF-7 cells. Sequence comparisons and molecular modeling of 83D4 indicate that the antibody combining site displays a cavity-like feature primarily defined by the CDR H1 and H2 loops. This pocket could accommodate a single Tn molecule, thus, suggesting a structural explanation for the predominant expression of a particular VH gene segment in a group of antibodies that recognize tumor-associated antigens arising from an aberrant O-glycosylation.. ...
CAMPATH-1 (CDw52) antibodies recognize a very small lipid-anchored glycoprotein that is expressed on the surface of human lymphocytes. They are remarkably lytic with human complement. In addition, CAMPATH-1G (rat IgG2b) and CAMPATH-1H (human IgG1) bind to human Fc receptors and are very effective for cell lysis in vivo. CAMPATH-1M (rat IgM) and CAMPATH-1G have been used to control GVHD and graft rejection in bone marrow transplantation by depletion of the T cells of the donor and recipient. Depletion of donor T cells alone gave excellent control of GVHD but up to 20% of the patients transplanted from HLA-matched siblings, and 51% of those transplanted from nonsibling donors, experienced graft failure caused by immunological rejection. Graft rejection could be partly overcome by additional immunosuppression either with CsA or total lymphoid irradiation (TLI). More effective was the use of CAMPATH-1G in vivo to deplete residual host lymphocytes. Preliminary results from current protocols of antibody
Abstract. Background: Acute graft-versus-host disease (GvHD) is mediated by activated T lymphocytes. Alemtuzumab is an unconjugated, humanized IgG1 kappa monoc
Colorful World of Quantum Dots. A few imaging applications using quantum dots (QDs) will be introduced, which will cover from visible to infrared(IR) for the wavelengths and from cellular super-resolution to whole body in vivo imaging for the object scale. (1) QDs were conjugated to tumor-specific antibodies(Abs) with zwitterionic surface coating to reduce nonspecific bindings. The Ab-QD probes were used to diagnose tumors for sectioned mouse tissues, fresh mouse colons stained ex vivo and in vivo, and also for fresh human colon adenoma tissues. The probes successfully detected not only cancers that are readily discernible by bare eyes but also hyperplasia and adenoma regions. Multiplexed QD, spray-and-wash, and endoscopy approach provided a significant advantage for detecting small or flat tumors that may be missed by conventional endoscopic examinations. QD-Ab probe was also used in conjunction with a ratiometric fluorescent molecular probe, cresyl violet-glutamic acid derivative, that ...
Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogramming effects on immune cell composition resulting in the restoration of tolerogenic networks. Alemtuzumab has proven high efficacy in clinical phase II and III trials, where interferon β-1a was used as active comparator. However, alemtuzumab is associated with frequent and considerable risks. Most importantly secondary autoimmune disease affects 30%-40% of patients, predominantly impairing thyroid function. Extensive monitoring and early intervention allow for an appropriate risk management. However, new and reliable biomarkers for individual risk stratification and treatment response to improve patient selection and therapy guidance are a significant unmet need. Only a deeper understanding of the
Mechanism of Action Alemtuzumab (Campath-1H) is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (,95%) normal lymphocytes, and T-cell & B-cell lymphoma cells. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and antitumour T-cell activity. Alemtuzumab has been used for chronic lymphocytic leukemia, low grade lymphomas and other non-cancerous indications.. ...
|strong|Human Anti-CD52 Antibody|/strong|, clone Campath-1H is a research grade biosimilar of the monoclonal antibody drug alemtuzumab. It is a recombinant human IgG1 kappa antibody with variable regi…
OBJECTIVE: To examine alemtuzumab efficacy in treatment-naive patients with highly active relapsing-remitting MS (RRMS). BACKGROUND: In CARE-MS I (NCT00530348), alemtuzumab significantly reduced clinical and MRI disease activity versus SC IFNB-1a over 2 years in the highly active patient subgroup. Efficacy was durable through 4 years, despite most receiving no therapy since Month 12. DESIGN/METHODS: Patients received courses of alemtuzumab at baseline and Month 12 in the core study. Patients could enter the extension (NCT00930553), with as-needed retreatment for relapse or radiological activity, or another disease-modifying therapy (DMT) at the investigators discretion. Highly active disease was ≥2 relapses in year before randomization and ≥1 baseline gadolinium-enhancing lesion. No evidence of disease activity (NEDA) was absence of MRI (new gadolinium-enhancing and new/enlarging T2 lesions) and clinical (6-month confirmed disability progression or relapse) activity. Brain volume loss was ...
View more ,Background: In the 2-year (y) CARE-MS II phase 3 trial (NCT00548405), alemtuzumab (12 mg/day; baseline: 5 consecutive days; 12 months later: 3 consecutive days) significantly improved clinical and MRI outcomes versus SC IFNB-1a in RRMS patients with inadequate response to prior therapy. In a 4-y extension (NCT00930553), patients could receive additional courses of alemtuzumab (12 mg/day on 3 consecutive days; ⩾12 months apart) as needed for disease activity or receive other disease-modifying therapy (DMT) per investigators discretion. Efficacy on clinical/MRI outcomes was maintained through Y6, with 50% receiving no additional alemtuzumab or other DMTs in the extension. Following the initial 4-y extension, patients could continue in TOPAZ (NCT02255656), an additional 5-y extension study, for further evaluation. Objectives: To evaluate 8-y efficacy and safety outcomes in alemtuzumab-treated CARE-MS II patients. Methods: At the investigators discretion, patients in TOPAZ can receive ...
If they had read our paper…… The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G.Mult Scler Relat Disord. 2020 May 12;43:102174. doi: 10.1016/j.msard.2020.102174. …..They would have known this.. Alemtuzumab is the sledge hammer to MS and it depletes your T and B cells and your MS goes away. So does your protective immune response, at least for a few weeks and this can be seen by the need to use treatments such as Acylovir to reduce viral infections. What happens to you when you get may predict disaster…howeverwe have made the case that the innate immune response is numero uno when it comes to kicking COVID-butt. The clinical experiment will give us the answer and there are a few case reports that support this view and the best one has just surfaced.. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab Eva Fernández-Díaz, Julia ...
The broad use of alemtuzumab in the routine clinical practice setting is feasible and active in unselected patients with pretreated CLL, and the current results confirmed the activity and safety of this agent, as reported in previously published clinical studies.
Recombinant monoclonal antibody manufactured using Recombinant Platform with variable regions from the hybridoma YNB46.1.8 (Campath 9-H) to detect CD4 expression in humans
Official pharmaceutical website with information regarding treatment for B-cell chronic lymphocytic leukemia for patients and health professionals. ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
LEMTRADA®, because of its risks, is generally for relapsing MS patients who have tried 2 or more MS medicines that didnt work well enough.
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Alemtuzumab belongs to the class of medications called selective immunomodulators. It is used to treat adults with relapsing remitting multiple sclerosis (RRMS) who are experiencing an active episode of RRMS and for whom other treatments have not been effective.
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab109185 交差種: Hu 適用: WB,IP,IHC-P,Flow Cyt,ICC/IF
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab92741 交差種: Ms,Rat 適用: WB,IHC-P
"Anti-Cathepsin K Antibody (A5871)". online catalog. Ltd. 2018. Retrieved 16 January 2018. Brömme ... 1 February 2013). "A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms". American Journal of Clinical Pathology. ... Cathepsin K antibodies are marketed for research into expression of this enzyme by various cells. Merck had a cathepsin K ... "Anti-Cathepsin K antibody (ab19027)". Abcam plc online catalog. Abcam plc. 2016. Retrieved 2 October 2016. " ...
They secrete high levels of antibodies, ranging from hundreds to thousands of antibodies per second per cell. Unlike their ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... These antibodies are transported from the plasma cells by the blood plasma and the lymphatic system to the site of the target ... Plasmablasts secrete more antibodies than B cells, but less than plasma cells. They divide rapidly and are still capable of ...
The antibody reactivity was due to a protein never known before, and is chemically responsive to all types of human and ... The protein was identified during investigations on the origin of multiple myeloma, a B-cell hematologic neoplasm. To ... "A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union". Science. 343 (6171): 656-661 ... nonhuman antibodies available. The protein is about 50 kDa in size, and composed of 556 amino acids. Future research must focus ...
Monoclonal neoplasm (tumor): A single aberrant cell which has undergone carcinogenesis reproduces itself into a cancerous mass ... Common usages of this term include: Monoclonal antibody: A single hybridoma cell, which by chance includes the appropriate V(D) ... In informal laboratory jargon, the monoclonal antibodies isolated from cell culture supernatants of these hybridoma clones ( ... J recombination to produce the desired antibody, is cloned to produce a large population of identical cells. ...
... serves to be a pan-B cell marker for the detection of B-cell neoplasms. However, tumor cells in some cases of T- ... "Anti-CD79 antibody induces B cell anergy that protects against autoimmunity". Journal of Immunology. 192 (4): 1641-50. doi: ... Other studies that focused on the deficiencies observed in neonatal antibody production can be due to various intrinsic ... lymphoblastic leukemia/lymphoma and AML has shown to potentially react positively with CD79 monoclonal antibodies. In addition ...
The most common neoplasm affecting the thyroid gland is a benign adenoma, usually presenting as a painless mass in the neck. ... These antibodies activate the receptor, leading to development of a goitre and symptoms of hyperthyroidism, such as heat ... Lastly, antibodies against components of the thyroid, particularly anti-TPO and anti-thyroglobulin, can be measured. These may ... Occasionally such antibodies block but do not activate the receptor, leading to symptoms associated with hypothyroidism. In ...
... may lead to secondary neoplasms in the patient.[citation needed] Topoisomerase I is the antigen recognized by Anti Scl-70 ... antibodies in scleroderma. Topoisomerases can fix these topological problems and are separated into two types depending on the ...
... uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell.[1] In cancer ... By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... links a molecule containing Iodine-131 to an anti-CD20 monoclonal antibody. It was withdrawn in 2014.[5] ... FF-21101(90Y) is a monoclonal antibody against P-cadherin radiolabeled with yttrium-90 (90Y).[6][7] ...
B lymphocytes kill pathogens by producing antibodies against them, while T lymphocytes directly kill them by engulfing them or ... Squamous cell carcinoma is a type of neoplasm that can affect lingual tonsils. Enlarged or hypertrophic lingual tonsils have ...
... or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic ... PCNA type 1 and type 2 Antibody Patterns". Antibody Retrieved 2008-04-15. Dan Krotz. "Structure of a clamp-loader ... Imaging of the nuclear distribution of PCNA (via antibody labeling) can be used to distinguish between early, mid and late S ... However, an important limitation of antibodies is that cells need to be fixed leading to potential artifacts. On the other hand ...
Where an underlying neoplasm is the cause, treatment of this condition is indicated in order to reduce progression of symptoms ... If the AAG is paraneoplastic, they have a form of cancer, and their immune system has produced paraneoplastic antibodies in ... Additionally, a blood test showing high levels of the antibody ganglionic nicotenic acetylcholine receptor (gAChr) occur in ... Paola Sandroni & Phillip A. Low (2009). "Other Autonomic Neuropathies Associated with Ganglionic Antibody". Autonomic ...
A Phase I study of Milatuzumab, a humanized anti-CD74 antibody, and Veltuzumab, a humanized anti-CD20 antibody, in patients ... CD74: a new candidate target for the immunotherapy of B-cell neoplasms. R. Stein, M.J. Mattes, T.M. Cardillo, H.J. Hansen, C.H ... Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. P. Sapra, R. Stein, J ... hLL1-Dox Milatuzumab has been linked to doxorubicin to form an antibody-drug conjugate or ADC (known as hLL1-Dox or IMMU-110) ...
... intraepidermal antibodies as well as along the dermoepidermal junction. Patients with low concentration of antibodies only ... in association with an underlying neoplasm". A study concluded in 2009, summarized in 2010, surrounded the surgical removal of ... Demonstration of certain antibodies in the serum was named as the basis for diagnosis of PNP. This piece labeled PNP as a " ... Specifically, antibodies against envoplakin and periplakin were being investigated. Further use of ELISA testing on these ...
Another important area where one can talk of "clones" of cells is neoplasms. Many of the tumors derive from one (sufficiently) ... These terms are most commonly used in context of antibodies or immunocytes. This concept of clone assumes importance as all the ... The B cells in the body have two important phenotypes (functional forms)-the antibody secreting, terminally differentiated ( ... Clone (B-cell biology) Cloning List of animals that have been cloned Polyclonal antibodies Polyclonal response Tumour ...
All women generated antibodies against hCG, but only 119 (80%) generated antibody titers clearly above 50 ng/mL, which was the ... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... In passive immunity the desired antibody titers are achieved by injecting antibodies directly into an animal. The efficacy of ... anti-sperm antibodies are not likely to have adverse health effects, since anti-sperm antibodies are produced by up to 70% of ...
Classification of the antibodies is based on their activity at different temperatures and their etiology. Antibodies with high ... Less common causes of warm-type AIHA include neoplasms other than lymphoid, and infection. Secondary cold type AIHA is also ... Usually, the antibody becomes active when it reaches the limbs, at which point it opsonizes RBCs. When these RBCs return to ... Antibodies are produced against the RBCs, which leads to complement activation. Complement fragments, such as C3a, C4a and C5a ...
... heterophile antibodies, enterocystoplasties, gestational trophoblastic diseases (GTD), and gestational trophoblastic neoplasms ... In the 1970s, the discovery of monoclonal antibodies led to the development of the relatively simple and cheap immunoassays, ... heterophilic antibody, familial hCG syndrome and cancer. Urine tests can be falsely positive in those that are taking the ... which is due to people having human antianimal or heterophilic antibodies. False positives can also be caused by (in order of ...
... antibodies, neoplasm MeSH D12.776.124.486.485.114.248 - antibodies, phospho-specific MeSH D12.776.124.486.485.114.252 - ... antibodies, neoplasm MeSH D12.776.124.790.651.114.248 - antibodies, phospho-specific MeSH D12.776.124.790.651.114.252 - ... antibodies MeSH D12.776.124.486.485.114.071 - antibodies, anti-idiotypic MeSH D12.776.124.486.485.114.089 - antibodies, ... antibodies, bispecific MeSH D12.776.124.486.485.114.143 - antibodies, blocking MeSH D12.776.124.486.485.114.167 - antibodies, ...
Only one type of light chain is present in a typical antibody, thus the two light chains of an individual antibody are ... with a highly divergent ratio indicative of neoplasm. The exact normal ratio of kappa to lambda, according to a novel ... The immunoglobulin light chain is the small polypeptide subunit of an antibody (immunoglobulin). A typical antibody is composed ... Monoclonal antibody Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2001). "Serum reference ...
Monoclonal antibodies against CD44 variants include bivatuzumab for v6. CD44 is a multistructural and multifunctional cell ... On the contrary, in some neoplasms CD44 upregulation is associated with a favorable outcome. This is true of prostate cancer, ... Experiments in animals have shown that targeting of CD44 by antibodies, antisense oligonucleotides, and CD44-soluble proteins ... markedly reduces the malignant activities of various neoplasms, stressing the therapeutic potential of anti-CD44 agents. High ...
The company also advanced other clinical-stage products, including Nimotuzumab, an EGFR-targeting monoclonal antibody, and ... which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and ... YM BioSciences' principal medicine of interest was a monoclonal antibody - Nimotuzumab - targeting the epidermal growth factor ...
Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies ... Antibody-drug conjugates (ADCs) are antibodies linked to one or more drug molecules. Typically when the ADC meets the target ... Four major antibody types that have been developed are murine, chimeric, humanised and human. Antibodies of each type are ... Initial therapeutic antibodies were murine analogues (suffix -omab). These antibodies have: a short half-life in vivo (due to ...
Currently antibodies to lipids and peptides in sera, detected by microarrays, can be used as markers of the pathological ... They look like intracranial neoplasms, and sometimes they get biopsied as suspected tumors. Proton MR spectroscopy can help in ... BBB is a tight vascular barrier between the blood and brain that should prevent the passage of antibodies through it, but in MS ... 2015). "Histopathology and clinical course of MOG-antibody-associated encephalomyelitis". Annals of Clinical and Translational ...
Although chemotherapy and hysterectomy are currently used in a clinical setting, the use of diverse treatments including anti- ...
Development of murine neoplasms started with work with the BALB/c mice to isolate the IgG1 secreting MOPC21 tumor. From this ... Several therapeutic antibody products are produced using the NS0 cell line including daclizumab and eculizumab. Barnes, LM; ... Galfrè, G; Milstein, C (1981). "Preparation of monoclonal antibodies: strategies and procedures". Methods in Enzymology. 73 (Pt ... NSo cells are naturally antibody-producing suspension cells with a lymphoblast morphology. Gene amplification is typically ...
Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study with monoclonal antibody A33. ... Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810-11813. ... Of the monoclonal antibodies developed in Dr. Old's laboratory, thirteen have been licensed and seven are in clinical trials. ... the anti-EGFr antibody Hu806, which Abbott Laboratories acquired exclusive world-wide rights to develop in a major licensing ...
Monoclonal antibodies e.g. rituximab (anti-CD20) and eculizumab (anti-C5) have been used but the therapeutic benefits are ... as well as hematological malignancies including non-Hodgkin lymphoma and myeloproliferative neoplasms. The exact pathogenesis ... As a weak, biphasic antibody, it absorbs to the P antigen in the cold temperature as in the periphery in the primary phase, and ... Autoimmune hemolytic anemia Warm-antibody type Primary Secondary (lymphoproliferative disorders, autoimmune disorders) Cold- ...
... monoclonal antibody - monoclonal antibody 3F8 - monocyte - Montanide ISA-51 - Morinda citrifolia - morphology - motexafin ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... bispecific antibody - bispecific monoclonal antibody - bisphosphonate - bizelesin - BL22 immunotoxin - black cohosh - black ... antibody - antibody therapy - anticachexia - anticancer antibiotic - anticarcinogenic - anticoagulant - anticonvulsant - ...
Intravascular leiomyomatosis is a benign neoplasm that extends through the veins; angioleiomyoma is a benign neoplasm of the ... Anti-smooth muscle antibodies (ASMA) can be a symptom of an auto-immune disorder, such as hepatitis, cirrhosis, or lupus. ... BBC - baby born with smooth muscle condition has 8 organs transplanted Smooth muscle antibody Stomach smooth muscle identified ... using antibody UIUC Histology Subject 265 Histology at KUMC muscular-muscle08 "Smooth Muscle" Histology image: 21701ooa - ...
... the plasmablasts in lymphoid neoplasms with plasmablastic differentiation do not mature into plasma cells or form antibodies ... Lymphoid neoplasms with plasmablastic differentiation were classified by the World Health Organization, 2017 as a sub-grouping ... In cases so infected, the lymphoid neoplasm may result, at least in part, from this viral infection and therefore can be ... The lymphoid neoplasms with plasmacytic differentiation are: 1) Plasmablastic lymphoma: The most common of these lymphoid ...
They secrete high levels of antibodies, ranging from hundreds to thousands of antibodies per second per cell.[5] Unlike their ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... Plasma cells can only produce a single kind of antibody in a single class of immunoglobulin. In other words, every B cell is ... The lifespan, class of antibodies produced, and the location that the plasma cell moves to also depends on signals, such as ...
2005). "Assessment of JC polyoma virus in colon neoplasms". Dis. Colon. Rectum. 48 (1): 86-91. doi:10.1007/s10350-004-0737-2. ... Padgett, B.L.; Walker, D.L. (1973). "Prevalence of antibodies in human sera against JC virus, an isolate from a case of ...
... neoplasm - nephrotoxic - neuralgia - neurological complications of AIDS - neuropathy - neutralization - neutralizing antibody ... antibodies - antibody-dependent cell-mediated cytotoxicity (ADCC) - antibody-mediated immunity - antifungal medication - ... functional antibody - fungus - fusin - fusion inhibitor - fusion mechanism - fusion peptide ...
Such antagonists include (but are not limited to) specific antibodies that target the molecule of interest, which act only in a ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ... "An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting ...
Targeting can also be achieved by attaching the radioisotope to another molecule or antibody to guide it to the target tissue. ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... CD20 monoclonal antibody conjugated to yttrium-90.[75] In 2003, the FDA approved the tositumomab/iodine (131I) tositumomab ... regimen (Bexxar), which is a combination of an iodine-131 labelled and an unlabelled anti-CD20 monoclonal antibody.[76] These ...
Antibodies against drotrecogin have been observed. There is insufficient data at this time to quantify the risk, but extreme ... Known or suspected intracranial neoplasm or mass lesion. *Known hypersensitivity to drotrecogin or any component ...
"Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative ...
ISBN 0-7020-2606-9. Huete-Garin, A.; S.S. Sagel (2005). "Chapter 6: "Mediastinum", Thymic Neoplasm". In J.K.T. Lee; S.S. Sagel ... Allergies involve mainly IgE, antibodies, and histamine. Mast cells release the histamine. Sometimes an allergen may cause a ... Myasthenia gravis is an autoimmune disease caused by antibodies that block acetylcholine receptors. Myasthenia gravis is often ...
In this therapy, mice are immunized with the CD19 antigen and produce anti-CD19 antibodies. Hybridomas developed from mouse ... "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): ... An extensive panel of monoclonal antibodies to cell surface markers, particularly CD or cluster of differentiation markers, are ... Blinatumomab, a CD19-CD3 bi-specific monoclonal murine antibody, currently shows promise as a novel pharmacotherapy. By ...
For advanced NSCLC, a combined chemotherapy treatment approach that includes cetuximab, an antibody that targets the EGFR ... Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed ... in that the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, ... advanced disease who are not found to have either EGFR or ALK mutations may receive bevacizumab which is a monoclonal antibody ...
Antibody-drug conjugates[edit]. Antibody-drug conjugates (ADCs) comprise an antibody, drug and a linker between them. The ... Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... Sievers EL, Linenberger M (Nov 2001). "Mylotarg: antibody-targeted chemotherapy comes of age". Current Opinion in Oncology. 13 ... They are divided into two groups: small molecule and antibodies. The massive toxicity seen with the use of cytotoxics is due to ...
"Neoplasms and cancer" has been chosen to reflect the fact that not all tumours are benign. The word "cancer" has been included ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... Approaches include antibodies, checkpoint therapy and adoptive cell transfer.[161] Laser therapy. Main article: Lasers in ...
Tseng-Tong Kuo, Classification of thymic epithelial neoplasms: a controversial issue coming to an end?, J.Cell.Mol.Med. 5. ... Nicolas JF, Reano A, Kaiserlian D, Thivolet J.,Epithelial cell heterogeneity in mammalian thymus: monoclonal antibody to high ... A unique thymic fibroblast population revealed by the monoclonal antibody MTS-15., J Immunol. 15. aprill 2007;178(8):4956-65., ... Researchers find cervical thymus that produces T cells and mounts antibody response, 3. märts 2006, (vaadatud 30.12.2014) ...
Monoclonal antibodies targeting both PD-1 and PD-L1, such as pembrolizumab, nivolumab,[183] atezolizumab, and durvalumab[182] ... Horn, L; Lovly, CM; Johnson, DH (2015). "Chapter 107: Neoplasms of the lung". In Kasper, DL; Hauser, SL; Jameson, JL; Fauci, AS ... Denosumab is a monoclonal antibody directed against receptor activator of nuclear factor kappa-B ligand. It may be useful in ... "Immunohistochemistry for Assessment of Pulmonary and Pleural Neoplasms: A Review and Update". Int J Clin Exp Pathol. 1 (1): 19 ...
Lung cancer is an extremely heterogeneous family of malignant neoplasms,[1] with well over 50 different histological variants ... monoclonal antibody against EGFR: *cetuximab (Erbitux)[12][unreliable medical source?]. *Inhibitors of vascular endothelial ...
Srikumar Chakravarthi; Baba Krishnan; Malathy Madhavan (1999). "Apoptosis and expression of p53 in colorectal neoplasms". ... It has been suggested that the presence of antibodies to Streptococcus bovis/gallolyticus antigens or the antigens themselves ... As summarized in the articles Carcinogenesis and Neoplasm, for sporadic cancers in general, a deficiency in DNA repair is ...
Neoplasms and cancer. *Inflammatory bowel disease. *Gluten sensitivity. *Other. *Symptoms and signs *eponymous ...
Skin with high permeability allowed quantum dots with an antibody attached to the surface for active targeting to successfully ... Diseases of the skin include skin infections and skin neoplasms (including skin cancer). ... May 2003). "Real-Time Vital Optical Imaging of Precancer Using Anti-Epidermal Growth Factor Receptor Antibodies Conjugated to ... "Expression of Human Skin-Specific Genes Defined by Transcriptomics and Antibody-Based Profiling". Journal of Histochemistry & ...
Antibodies against glucagon, secreted by alpha cells, show their peripheral position. Antibodies against insulin, secreted by ... "Solid pseudopapillary neoplasm of the pancreas: a single institution experience of 14 cases". HPB. 8 (2): 148-50. doi:10.1080/ ... A pancreatic islet that uses fluorescent antibodies to show the location of different cell types in the pancreatic islet. ... "The Human Pancreas Proteome Defined by Transcriptomics and Antibody-Based Profiling". PLOS ONE. 9 (12): e115421. Bibcode ...
Antibodies: Against TrkA: GBR-900; Against NGF: ABT-110 (PG110). *ASP-6294 ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ...
Targeting can also be achieved by attaching the radioisotope to another molecule or antibody to guide it to the target tissue. ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... CD20 monoclonal antibody conjugated to yttrium-90.[81] In 2003, the FDA approved the tositumomab/iodine (131I) tositumomab ... genetics and prevention of secondary neoplasms in adult cancer survivors". Nature Reviews Clinical Oncology. 10 (5): 289-301. ...
Antibody-mediated *Warm autoimmune hemolytic anemia is caused by autoimmune attack against red blood cells, primarily by IgG. ... and a number of neoplasms of the bone marrow.[1] Causes of increased breakdown include a number of genetic conditions such as ...
Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ... a monoclonal antibody that attacks white blood cells, has been used in treatment with greater success than previous options.[56 ... classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937-51. doi:10.1182/ ... These disorders may evolve into chronic eosinophilic leukemia or may be associated with various forms of myeloid neoplasms, ...
Occasionally such antibodies block but do not activate the receptor, leading to symptoms associated with hypothyroidism.[77] In ... The most common neoplasm affecting the thyroid gland is a benign adenoma, usually presenting as a painless mass in the neck.[64 ... These antibodies activate the receptor, leading to development of a goitre and symptoms of hyperthyroidism, such as heat ... Antibodies against thyroid peroxidase can be found on testing. The inflammation usually resolves without treatment, although ...
Antibodies that develop following an initial infection with a type of HSV prevents reinfection with the same virus type-a ... Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ... Until the 1980s serological tests for antibodies to HSV were rarely useful to diagnosis and not routinely used in clinical ... Laboratory tests include culture of the virus, direct fluorescent antibody (DFA) studies to detect virus, skin biopsy, and ...
"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms". N Engl J Med 369 (25): 2379-90. PMID 24325356. doi:10.1056/ ... "Congenital Heart Block Not Associated with Anti-Ro/La Antibodies: Comparison with Anti-Ro/La-positive Cases". J. Rheumatol. 36 ... "Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2". N Engl J Med 369 (25): 2391-405. PMC 3966280 ... "Interactions of NK cell receptor KIR3DL1*004 with chaperones and conformation-specific antibody reveal a functional folded ...
In fact, he is capable of making antibodies against them.. Injection of sperm antigens causes inflammation of the testis (auto- ... Testicular cancer and other neoplasms - To improve the chances of catching possible cases of testicular cancer or other health ... "The human testis-specific proteome defined by transcriptomics and antibody-based profiling". MHR: Basic science of ...
... of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms. Rancés ... Monoclonal Antibody. We used 14F7 Mab, produced at the Center of Molecular Immunology (Havana, Cuba) as previously described [ ... A study with specific monoclonal antibodies," Cancer, vol. 65, no. 3, pp. 499-505, 1990. View at Google Scholar ... BCC and SCC are malignant neoplasms arising from the keratinocytes, cells of ectodermal origin that usually show a slower and ...
... the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies ... invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. ... 1) an anti-CXCL13 antibody, a fragment of an anti-CXCL13 antibody, an anti-CXCR5 antibody, or a fragment of an anti-CXCR5 ... 1) an anti-CXCL13 antibody, a fragment of an anti-CXCL13 antibody, an anti-CXCR5 antibody, or a fragment of an anti-CXCR5 ...
... the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy ... Antibodies. *FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and ... ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and ... FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123- ...
T1 - Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ... Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ... Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ... Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ...
Streamlining Immuno-Oncological Therapeutic Antibody Discovery. Tracey Mullen. The growing trend of implementing immunotherapy ... Neoplasm News and Research. RSS Neoplasm is an abnormal mass of tissue as a result of neoplasia. Further Reading. *Neoplasm - ... Common drug for autoimmune disease may increase risk of myeloid neoplasms Mayo Clinic researchers have found that azathioprine ... infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients, two years of ...
Antibodies neoplasm in the largest biology dictionary online. Free learning resources for students covering all major areas of ... Antibodies, neoplasm. immunoglobulins induced by antigens specific for tumours other than the normally occurring ...
Antibodies, Bacterial/blood. *Carcinoma, Squamous Cell/complications*. *Carcinoma, Squamous Cell/epidemiology. *Case-Control ... Helicobacter pylori infection is associated with a decreased risk of developing oesophageal neoplasms.. Henrik Simán J1, ... Current smokers and ex-smokers have instead a definite increased risk of oesophageal neoplasms. ... High alcohol consumption was no longer significantly associated with oesophageal neoplasms after tobacco smoking was included ...
... was used for the analysis of cell kinetics of cutaneous keratinocytic neoplasms. The antibody is applicable to formalin-fixed, ... Immunohistochemical study with a monoclonal antibody (TOB7) used against proliferating cell nuclear antigen.. Saida T1, Dohi S ... In the present study, a murine monoclonal antibody (TOB7) against the proliferating cell nuclear antigen (PCNA) ... Important information on the growth dynamics of keratinocytic neoplasms was obtained in this retrospective immunohistochemical ...
Table 1. Antibodies and immunohistochemical protocols used in hepatobiliary neoplasms in cats ... lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to ... lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to ... lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to ...
Antibodies, Monoclonal, Humanized / therapeutic use* * Antirheumatic Agents / therapeutic use* * Arthritis, Rheumatoid / drug ... Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept ... Objective: To assess the risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with bDMARDs. ... Main outcomes and measures: Outcomes included a first invasive solid or hematologic malignant neoplasm, or skin cancer. Hazard ...
We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. ... Following internalization, anti-SAIL antibody-drug conjugates (ADCs) exhibited subnanomolar IC50 values against AML cell lines ... Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions *Christian M. Schürch ... Antibody-drug conjugates represent a promising new class of anticancer therapeutics that combine the specificity of an antibody ...
Antibodies and Western Blotting. Samples for Western blotting were prepared by lysing 106 cells in radioimmunoprecipitation ... Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Joan Montero, Jason Stephansky, ... Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: Focus on biallelic locus 9p21.3 deletion. Blood 2011;118:4591 ... BPDCN has had many prior names, including CD4+CD56+ hematodermic neoplasm, blastic natural killer cell lymphoma, and agranular ...
Anticerebellar antibodies in neurologically normal patients with ovarian neoplasms. H. Robert Brashear, John E. Greenlee, Kurt ... Anticerebellar antibodies in neurologically normal patients with ovarian neoplasms. Together they form a unique fingerprint. * ...
Drug: Antibody TF2. *Radiation: IMP-288-Lutetium. *Radiation: IMP-288-Indium. Interventional. Phase 1. Phase 2. *Centre René ... 442 Studies found for: lung neoplasms AND (woman OR women OR female) ...
Evaluate the seroconversion rate of HPV antibodies in serum after vaccination.. 135. All. 9 Years to 30 Years (Child, Adult). ... Production of a panel of monoclonal antibodies to ERRα1 by standard hybridoma methods that can be used to distinguish between ... neoplasms [CONDITION] AND child [AGE-GROUP] , Recruiting, Not yet recruiting, Available Studies (1984 records) ... Correlation of the results of IHC studies on archival paraffin sections of primary breast tumors using monoclonal antibodies to ...
Neoplasms by Histologic Type. Neoplasms, Glandular and Epithelial. Neoplasms, Nerve Tissue. Liver Diseases. Antibodies. ... Head and Neck Neoplasms. Liver Neoplasms. Digestive System Neoplasms. Neoplasms by Site. Neoplasms. Endocrine Gland Neoplasms. ... Neoplasm. Malignancy. Intratumoral. Intralesional. anti-PD-1 antibodies. Immuno therapy. Dose escalation. Platinum. Intensity ... Neoplasms, Neuroepithelial. Neuroectodermal Tumors. Neoplasms, Germ Cell and Embryonal. ...
Potential symptoms of plasma cell neoplasms include fatigue, bone pain, weakness and fevers, says the National Cancer Institute ... Plasma cell neoplasms can cause plasma cells to manufacture the M protein antibody, a fault that leads to abnormally thick ... These abnormal antibodies may harm kidneys as well. Most cancerous plasma cell neoplasms are classifed as plasmacytoma, or ... A plasma cell neoplasm is a disease that causes the human body to produce too many plasma cells, reports the National Cancer ...
Antibodies, Monoclonal, Humanized / pharmacology * Antibodies, Monoclonal, Humanized / therapeutic use * Antigens, Neoplasm / ...
Neoplasm Metastasis. Neoplasms. Neoplastic Processes. Pathologic Processes. Durvalumab. Antibodies, Monoclonal. Antineoplastic ... Solid Tumor Metastatic Tumor Locally Advanced Malignant Neoplasm Unresectable Malignant Neoplasm Drug: SNDX-6352 Drug: ... Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).. *Known active hepatitis B (e.g., hepatitis B surface ... Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. ...
... typing as a tool for a more precise characterization of the origin and differentiation of human neoplasms. ... "Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ... Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ... Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ...
... intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g. small cell and non-small ... A TIM-3 binding molecule wherein the TIM-3 binding molecule is an antibody specific for TIM-3 or is a fragment of an antibody ... monoclonal antibody] against experimental and carcinogen-induced tumors (see the abstract). The anti-TIM-3 antibodies used ... T 1602/10 (Anti-TIM-3 antibodies for the treatment of cancer/BRIGHAM) of 17.3.2015. European Case Law Identifier:. ECLI:EP:BA: ...
readers will learn when to order antibodies and how to interpret findings. In addition, prognostic markers are evaluated and ... Applied Immunohistochemistry in the Evaluation of Skin Neoplasms will serve as an extremely valuable resource for practicing ... Applied Immunohistochemistry in the Evaluation of Skin Neoplasms. Editors: Plaza, Jose A., Prieto, Victor G (Eds.) ... The book reviews in detail the sensitivity and specificity of commonly available antibodies and their pattern of immunostaining ...
ICD-9 code 146.1 for Malignant neoplasm of tonsillar fossa is a medical classification as listed by WHO under the range - ... on the costs associated with administering monoclonal antibodies. CMSThe post New Codes Rates for COVID19 Therapeutics appeared ... Malignant neoplasm of tonsillar fossa (146.1). ICD-9 code 146.1 for Malignant neoplasm of tonsillar fossa is a medical ... classification as listed by WHO under the range -MALIGNANT NEOPLASM OF LIP, ORAL CAVITY, AND PHARYNX (140-149).. ...
NEOPLASMS; PLANT TISSUES; PROTEINS; RADIATION DOSES; SPLEEN; UPTAKE. ... Tumor ratios were larger and independent of antibody type. Aside from tumor, the R ratio of uptakes depended on the antibody ... 60 APPLIED LIFE SCIENCES; ANIMAL TISSUES; ANTIBODIES; CARCINOEMBRYONIC ANTIGEN; CEA; HUMAN POPULATIONS; INDIUM; INDIUM 111; ... Antibodies included diabody (56 kDa), minibody (80kDa) and intact M5A (150 kDa) anti-CEA cognates. Both radioiodine and indium- ...
Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. Previous ... there have been no reports attempting to more comprehensively profile the landscape of prostate cancer-associated antibodies. ...
Plasma cell neoplasms are a group of diseases - some cancerous - where certain blood cells dont work like they should. Learn ... But with the group of diseases known as plasma cell neoplasms, your body makes too many plasma cells. They make an antibody ... Plasma cell neoplasms can lead to amyloidosis. This is a condition where proteins build up in your organs, like the kidneys and ... In some plasma cell neoplasms, the cells are cancer and form tumors, usually in your bones. The symptoms you get and the ...
C with each primary antibody and incubated for 1 hour at room temperature with secondary antibodies. Proteins were visualized ... pancreatic intraepithelial neoplasm (PanIN) (5, 6) and intraductal papillary mucinous neoplasm (IPMN) (7, 8). These ... Intraductal papillary mucinous neoplasm: a clinicopathologic review. Surg Clin North Am. 2010;90(2):377-398.. View this article ... Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J Clin ...
ICD-9 code 202.91 for Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of ... Reporting Eli Lillys Antibody Combo Therapy Medicare releases two new codes for combination bamlanivimab and etesevimab the ... Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of head face and neck ( ... ICD-9 code 202.91 for Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of ...
Each bead can be coated with capture antibodies specific for a given antigen. After antigen capture, secondary antibodies ... NEOPLASMS; OVALBUMIN; PATHOGENS; POLYSTYRENE; PROSTATE. ...
Xencor has acknowledged that the FDA has placed the companys Phase I trial of its CD123 x CD3 bispecific antibody XmAb®14045 ... Those malignancies include B-cell acute lymphoblastic leukemia; blastic plasmacytoid dendritic cell neoplasm; and the blast ... XmAb14045 is a tumor-targeted antibody that contains both a CD123 binding domain and the cytotoxic T-cell binding domain CD3. A ... Xencor acknowledged today that the FDA has placed the companys Phase I trial of its CD123 x CD3 bispecific antibody XmAb®14045 ...
  • SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve and previously-treated populations. (
  • The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients, two years of age and older. (
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. (
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration ( 1 ). (
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as natural killer (NK) cell leukemia/lymphoma, is categorized by the World Health Organization (4th edition, 2008) under acute myeloid leukemia (AML). (
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is very often misdiagnosed and under-reported. (
  • A new trial "SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia" is now open for enrollment. (
  • Antibodies , neoplasm immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens . (
  • Anti-neuronal antibodies are classified into antibodies against cell surface antigens (CSAab), antibodies against synaptic antigens (SyAab) and antibodies against intraneuronal antigens (INAab), also known as onconeural antibodies 6 , 7 . (
  • Expression of cDNA libraries from human melanoma, renal cancer, astrocytoma, and Hodgkin disease in Escherichia coli and screening for clones reactive with high-titer IgG antibodies in autologous patient serum lead to the discovery of at least four antigens with a restricted expression pattern in each tumor. (
  • The unexpected frequency of human tumor antigens, which can be readily defined at the molecular level by the serological analysis of autologous tumor cDNA expression cloning, indicates that human neoplasms elicit multiple specific immune responses in the autologous host and provides diagnostic and therapeutic approaches to human cancer. (
  • In addition to these autoantibodies, patients with thymoma-associated MG produce autoantibodies to various neuromuscular antigens, including antibodies to the skeletal muscle calcium release channel (ryanodine receptor of sarcoplasmic reticulum) and antibodies to cytoplasmic filamentous proteins (particularly titin) or neurofilaments. (
  • her antinuclear antibodies (ANA), rheumatoid factor, complete blood count, anti-extractable nuclear antigens, and anti-double-stranded DNA levels were all within normal limits. (
  • Immune- mediated paraneoplasia is identified by antibody activity with any of a small but growing collection of organ-specific antigens demonstrated to have a distinct disease association and an apparent involvement in autoimmunity. (
  • Immune-mediated paraneoplasia (IMP) is a collection of cancer- associated syndromes that involve pathological immunological activity.1-3 Autoimmunity is implicated by reports of patients displaying abnormal antibody reactions focused on single antigens expressed within the affected organ. (
  • Acceptance of an immunological cause and effect led to the use of serological assays that detect abnormal antibody activity with a growing collection of paraneoplasia-associated antigens. (
  • Roelcke D. The Lud cold agglutinin: a further antibody recognizing N-acetylneuraminic acid-determined antigens not fully expressed at birth. (
  • The expression of antigens by various neoplasms lead to antibody formation that may induce an intrathecal inflammatory process leading to distinct neurological symptoms [ 4 , 5 ]. (
  • Plasma cells, also called plasma B cells, are white blood cells that originate in the bone marrow and secrete large quantities of proteins called antibodies in response to being presented specific substances called antigens. (
  • Immunohistochemical study with a monoclonal antibody (TOB7) used against proliferating cell nuclear antigen. (
  • In the present study, a murine monoclonal antibody (TOB7) against the proliferating cell nuclear antigen (PCNA) was used for the analysis of cell kinetics of cutaneous keratinocytic neoplasms. (
  • Each bead can be coated with capture antibodies specific for a given antigen. (
  • After antigen capture, secondary antibodies sandwich the bound antigen and are indirectly labeled by the fluorescent reporter phycoerythrin (PE). (
  • The CC49 antibody dosages below saturation of the tumour antigen level were first examined for the LS174T tumour mouse model. (
  • Then the MPTAs of the antibody in mice bearing tumours of different sizes were determined, always at antibody dosages below antigen saturation. (
  • These pathways complement our catalog of research reagents for the study of Malignant Paraganglionic Neoplasm including antibodies and ELISA kits against CARCINOEMBRYONIC ANTIGEN, KLK3, BCL2, CD34, CDKN1A. (
  • These plasma cells produce large amounts of antibody that are specific for the antigen. (
  • Antibodies are large proteins called immunoglobulins (Igs) that bind to and remove the specific antigen. (
  • Antibodies to a given antigen were usually confined to patients with the same tumor type. (
  • This algorithm depicts the reflex path for the HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes assay (Test Code 91431). (
  • A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. (
  • Two polyclonal rabbit antibodies to epithelial membrane antigen (EMA), two mouse monoclonal antibodies (E29 and HMFG-2), and a 'cocktail' of these two monoclonals have been compared using an indirect immunoperoxidase technique. (
  • Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. (
  • Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. (
  • Moreover, specific antigen recognition of antibodies in neuronal tissue induces characteristic neurological symptoms. (
  • Antibodies have been used for antigen detection and therapeutics, and their specificity combined with low toxicity make them a promising pharmaceutical commodity [ 1 ]. (
  • These antibodies are transported from the plasma cells by the blood plasma and the lymphatic system to the site of the target antigen (foreign substance), where they initiate its neutralization or destruction. (
  • This process favors, by selection for the ability to bind antigen with higher affinity, the activation and growth of B cell clones able to secrete antibodies of higher affinity for the antigen. (
  • Unlike their precursors, they cannot switch antibody classes, cannot act as antigen-presenting cells because they no longer display MHC-II, and do not take up antigen because they no longer display significant quantities of immunoglobulin on the cell surface. (
  • However, higher ERBB1 expression predicted susceptibility to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred independently of KRAS/BRAF/PIK3CA mutations ( P = 0.69). (
  • This antibody effectively killed melanoma cells in vitro via antibody-mediated cellular cytotoxicity. (
  • Metuzumab is an affinity-optimized and nonfucosylated anti-CD147 human-mouse chimeric IgG1 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). (
  • Normally, they make antibodies -- proteins to help kill germs that enter your body. (
  • IgG antibodies to the capsid proteins of JCV and BKV were assessed using ELISAs. (
  • Although well established, this technology is laborious, and it is biased by the experimental animal immune system, which limits the ability to reach a high-affinity antibody against conserved mammal proteins. (
  • Additionally, the heterologous character of those proteins turn them often immunogenic to humans eliciting HAMA response (Human Anti-Mouse Antibodies), which restrict their therapeutic use [ 5 ]. (
  • In some plasma cell neoplasms, the cells are cancer and form tumors, usually in your bones. (
  • The tumors you get with plasma cell neoplasms can also damage your bones. (
  • Molecular studies of lymphoblastic B-cell lymphoma, the most prevalent neoplasm (50% of all tumors), showed that the lymphomas were clonal, overexpressed Myc His , and exhibited the P2 to P1 promoter shift in Myc expression, a hallmark of MYC/Myc deregulation in human endemic Burkitt lymphoma and mouse plasmacytoma. (
  • Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study. (
  • Therefore, anti-ERBB1 antibodies may be considered in CRC tumors with higher ERBB1 expression and favorable FcγR polymorphisms. (
  • We conducted a case-control study, nested within a prospective cohort, to investigate the association between antibodies to JCV, BKV, and SV40, as measured in serum collected 1-22 years before diagnosis and incident primary malignant brain tumors. (
  • We conducted a population-based, nested case-control study, comparing the presence of polyomavirus antibodies in serum collected years before diagnosis between incident cases of primary brain tumors and cancer-free controls. (
  • Since the advent of phage display technology, dating back to 1985, antibody libraries displayed on filamentous phage surfaces have been used to identify specific binders for many different purposes, including the recognition of tumors. (
  • There are rare benign diseases that can mimic malignant breast neoplasms in the clinical exam and in mammography. (
  • Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey. (
  • The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. (
  • We describe an approach, including a cell-based ELISA, to evaluate mature IgG antibody responses to melanoma from human peripheral blood B cells. (
  • Overall, 28% of melanoma patient-derived B cell cultures (n = 1,800) compared to 2% of cultures from healthy controls (n = 600) produced antibodies that recognized melanoma cells. (
  • Lastly, a patient-derived melanoma-specific monoclonal antibody was selected for further study. (
  • These data demonstrate the presence of a mature systemic B cell response in melanoma patients, which is reduced with disease progression, adding to previous reports of tumor-reactive antibodies in patient sera, and suggesting the merit of future work to elucidate the clinical relevance of activating humoral immune responses to cancer. (
  • While basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are malignant neoplasms with a low lethality and a good prognosis [ 2 ], the 10-year survival rate is 92% among the patients with T1 melanomas, and is 50% in patients with T4 melanomas [ 3 ]. (
  • Squamous cell carcinoma and Bowen's disease showed significantly increased numbers of PCNA-positive cells when compared with other keratinocytic neoplasms. (
  • Cholangiocarcinoma was the most commonly diagnosed neoplasm, followed by hepatocellular carcinoma and hemangiosarcoma. (
  • A monoclonal antibody (H17E2) against placental alkaline phosphatase (PLAP) and testicular placental-like alkaline phosphatase was labelled with indium-111 and used in radioimmunoscintigraphy of 15 patients known or suspected to have germ-cell carcinoma of the testis or carcinoma of the ovary or cervix. (
  • A series of metastatic breast carcinoma (MBC) mimicking visceral well-differentiated neuroendocrine neoplasms has not previously been reported. (
  • Metaplastic carcinoma of the breast (MpBC) is defined as a group of heterogeneous malignant neoplasms that contain glandular and non-glandular components with mixed epithelial and mesenchymal differen. (
  • The potentially aggressive course of sebaceous carcinoma necessitates accurate differentiation from benign sebaceous neoplasms. (
  • Thus as part of study IT-01 the Sponsor will seek to understand the safety and efficacy of INT230-6 when administered in combination with immuno-therapeutic agents such as antibodies that target Programmed Cell Death (PD-1 or anti-PD-1) receptors. (
  • The reason given for the refusal was that, although the application disclosed that mice with experimental autoimmune encephalomyelitis (EAE) treated with anti-TIM-3 antibodies exhibited exacerbated disease, this was not a therapeutic benefit and did not enable the skilled person to carry out the claimed invention. (
  • Custom antibody development and commercial partnerships to advance your diagnostic and therapeutic discovery. (
  • Development of accurate therapeutic approaches to salivary gland neoplasms depends on better understanding of their molecular pathogenesis. (
  • Therapeutic use of antibodies is limited by methodological constraints in raising them. (
  • hyperthyroidism caused by antibodies to TSH receptors. (
  • B cells differentiate into plasma cells that produce antibody molecules closely modeled after the receptors of the precursor B cell. (
  • IMGN632 is an antibody drug conjugate that targets CD123 positive malignancies including BPDCN, AML and ALL. (
  • The current investigation emphasized the efficiency of immunohistochemistry (IHC) typing as a tool for a more precise characterization of the origin and differentiation of human neoplasms. (
  • Implications for diagnosis of human neoplasms. (
  • Outcomes included a first invasive solid or hematologic malignant neoplasm, or skin cancer. (
  • The observed numbers of events (crude incidence per 100 000 person-years) for a first invasive solid or hematologic malignant neoplasm were 50 (959) for tocilizumab, 61 (1026) for abatacept, 141 (1074) for rituximab, 478 (978) for initiators of TNFi as first bDMARD, and 169 (917) for TNFi as second bDMARD. (
  • ICD-9 code 146.1 for Malignant neoplasm of tonsillar fossa is a medical classification as listed by WHO under the range -MALIGNANT NEOPLASM OF LIP, ORAL CAVITY, AND PHARYNX (140-149). (
  • ICD-9 code 202.91 for Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of head face and neck is a medical classification as listed by WHO under the range -MALIGNANT NEOPLASM OF LYMPHATIC AND HEMATOPOIETIC TISSUE (200-208). (
  • Considering taking medication to treat primary malignant neoplasm of peritoneum? (
  • Below is a list of common medications used to treat or reduce the symptoms of primary malignant neoplasm of peritoneum. (
  • These pathways complement our catalog of research reagents for the study of Liver Neoplasms, Experimental including antibodies and ELISA kits against GLUTATHIONE TRANSFERASE, GLUTATHIONE S-TRANSFERASE, GST-P, AFP, ALB. (
  • In recent years, the development of antibody-drug conjugates (ADCs) has become an effective approach for the treatment of cancer. (
  • Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates. (
  • Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to Cytokeratin and Vimentin', Iranian Journal of Pathology , 13(1), pp. 23-29. (
  • Xencor acknowledged today that the FDA has placed the company's Phase I trial of its CD123 x CD3 bispecific antibody XmAb®14045 on a partial clinical hold following the deaths of two patients linked to the blood cancer candidate. (
  • XmAb14045 has been under study in the Phase I trial ( NCT02730312 ), designed to assess the safety and tolerability of weekly intravenous administration of the bispecific antibody candidate in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies. (
  • Furthermore, the isotype and specificity of the antibodies produced by plasma cells can drive distinct immune responses. (
  • Limited research has focused on B cells and the specificity of antibodies they produce in cancer. (
  • Methods: Twenty patients with mature T-cell neoplasms and 44 patients without evidence of T-cell neoplasia were studied. (
  • IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world. (
  • To assess the risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with bDMARDs. (
  • To measure antibody-dependent cytotoxic activity (ADCC) in patients receiving lenalidomide plus cetuximab. (
  • PURPOSE: To describe oncolytic effects of treatment with anti-G(D2) monoclonal antibody 3F8 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with neuroblastoma (NB). (
  • Patients without progressive disease (PD) or elevated human antimouse antibody titers could be treated again beginning 3 weeks after completion of a cycle. (
  • Patients may have antibodies of more than one type, and CSAab and SyAab may be present together with anti-INAab, especially in paraneoplastic AIE. (
  • Patients receive one dose of astatine At 211 antitenascin monoclonal antibody 81C6 (At 211 MAb 81C6) via the intralesional catheter. (
  • Determine the toxic effects of intracranial iodine I 131 labeled anti-tenascin monoclonal antibody 81C6 in patients with primary or metastatic anaplastic gliomas. (
  • Patients with a history of a renal neoplasm presenting with acute neurological signs or symptoms should undergo which of the following imaging studies? (
  • A significant proportion of colorectal cancer (CRC) patients are resistant to anti-ERBB1 [avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, receptor for EGF] monoclonal antibodies (Mabs). (
  • Mutations in JAK2, MPL, or CALR are detected in more than 80% of myeloproliferative neoplasm (MPN) patients and are thought to play a driver role in MPN pathogenesis via autosomal activation of the JAK-STAT signaling cascade. (
  • However, six pedigrees were suggestive for a hereditary breast and ovarian cancer syndrome, three of a Li-Fraumeni like syndrome, and three index patients showed multiple primary neoplasms. (
  • 7 , 8 The demonstration of increased familial tumour risk in patients with AML following a primary neoplasm further supported the concept of genetic susceptibility to t-MNs. (
  • Antibodies against a presynaptic structure, the voltage-gated potassium channels of peripheral nerves, have been detected in patients with neuromyotonia with or without thymoma. (
  • Neuromyotonia and antibodies to the voltage-gated potassium channels have also been found in patients with MG. Twenty percent of patients with MG and neuromyotonia have been demonstrated to have thymoma. (
  • Here we describe 3 pediatric patients with linear scleroderma en coup de sabre who presented with neurologic abnormalities before or concurrent with the diagnosis of their skin disease. (
  • Our patients' cases highlight the underrecognized relationship between neurologic complications and linear scleroderma en coup de sabre and illustrate the importance of a thorough skin examination in patients with unexplained neurologic disease. (
  • Their cases illustrate the variability in neurologic manifestations of linear scleroderma en coup de sabre as well as the importance of a careful skin examination in patients with unexplained neurologic disease. (
  • Our objective was to investigate the quantitative expression of BCL-2 (anti-apoptotic), BAX and Caspase3 (pro-apoptotic genes) mRNAs in salivary gland neoplasms and examine the association of these data with tumour size, proliferative activity and p53 staining (parameters associated with a poor prognosis of salivary tumours patients). (
  • There are few cases describing concomitant neurological symptoms in patients with neuroendocrine neoplasms, however, mostly due to excessive hormone release and seldomly correlated to positive antibodies [ 6 ]. (
  • This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). (
  • Thus, homologous MYC/Myc -Eμ rearrangements lead to B-cell and plasma-cell neoplasms in humans and mice. (
  • The antibodies block high affinity interactions leading to the growth or migration of cancer cells. (
  • 1. A TIM-3 binding molecule wherein the TIM-3 binding molecule is an antibody specific for TIM-3 or is a fragment of an antibody specific for TIM-3, for use in the treatment of cancer in a subject. (
  • Potential symptoms of plasma cell neoplasms include fatigue, bone pain, weakness and fevers, says the National Cancer Institute. (
  • A plasma cell neoplasm is a disease that causes the human body to produce too many plasma cells, reports the National Cancer Institute. (
  • The collaboration was also designed to generate an eventual up-to-$2.4 billion in development, regulatory, and sales milestone payments for Xencor, a Monrovia, CA, biopharma focused on developing antibodies for treating cancer as well as autoimmune diseases, asthma, and allergic diseases. (
  • After adjustment for smoking and other sexually transmitted diseases, antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval 1.6-15.7)), but the numbers were too small for drawing conclusions as to the sexually transmitted diseases with which cervical cancer is most specifically associated. (
  • Metastatic breast Cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs. (
  • Monoclonal antibodies against the epidermal growth factor receptor, ERBB1 [avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, receptor for EGF], including in particular cetuximab, are now commonly used in colorectal cancer (CRC) treatment ( 1 ⇓ - 3 ). (
  • SINGAPORE, October 13, 2020 / B3C newswire / -- Prestige BioPharma Ltd. (hereinafter "Prestige BioPharma") today announced that the European Medicines Agency (EMA) Orphan Drug Commission (COMP) has granted a positive opinion for an Orphan Drug Designation (ODD) status to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer. (
  • Has anyone had a follicular neoplasm which turned out to be cancer of the thyroid? (
  • Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins. (
  • Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer. (
  • Phage display represents a high-throughput technique for screening billions of random fusion antibodies against virtually any target on the surface or inside cancer cells, or even soluble markers found in patient serum. (
  • NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADC™) products. (
  • Antibody-Drug Conjugate Development. (
  • Less well understood, but of growing interest, is the interaction between cells in the bone marrow during the initiation, maintenance and treatment of hematologic neoplasms. (
  • ab91357 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. (
  • These depend on which type of plasma cell neoplasm you have. (
  • WM is a type of plasma cell neoplasm or B-cell lymphoma. (
  • It was held that post-published evidence of reduction of tumour growth in a tumour model by treatment with anti-TIM-3 antibody could not remedy the deficiency because sufficiency of disclosure had to be established at the filing or priority date of the application, as the case may be. (
  • Our previous studies have indicated that the optimal dosage ratio of pretargeting antibody to effector is proportional to their maximum percent tumour accumulations (MPTAs). (
  • The MPTAs versus tumour sizes for both the antibody and the effector were fitted non-linearly. (
  • The best fit of the antibody MPTA (Y(antibody)) with tumour size (x) in grams was Y(antibody)=19.00 x(-0.65) while that for the effector was Y(effector)=4.51x(-0.66). (
  • Thus, even though the MPTAs of both vary with tumour size, the ratio (Y(antibody)/Y(effector)) is a constant at 4.21. (
  • In conclusion, the MPTA ratio of the antibody to the effector was found to be constant with tumour size, an observation that will simplify pretargeting optimisation because remeasurement of the optimum dosage ratio for different tumour sizes can be avoided. (
  • Here we summarize our current knowledge of the roles of B cells and antibodies in the tumour microenvironment. (
  • Fig. 1: Antitumour roles of tumour-infiltrating B cells and intratumourally produced antibodies. (
  • In conclusion, we show an anti-apoptotic gene expression profile in salivary neoplasms in association with p53 staining, but independent of cell proliferation and tumour size. (
  • Most cancerous plasma cell neoplasms are classifed as plasmacytoma, or multiple myeloma. (
  • The titer of antibodies to tumor cells, as estimated by membrane immunofluorescence, was also higher in the GR strain. (
  • Applied Immunohistochemistry in the Evaluation of Skin Neoplasms will serve as an extremely valuable resource for practicing dermatopathologists and pathologists. (
  • Sebaceoma, originally described by Troy and Ackerman [ 1 ], is a distinct benign sebaceous neoplasm that is histopathologically characterized by dermal aggregations of sebaceous germinative cells and sebaceous duct-like or cyst-like structures. (
  • Caution is necessary when using adipophilin to distinguish sebaceous neoplasms from other cutaneous lesions with clear cell histology. (
  • 5,6) Xanthomatous lesions, including xanthelasma and xanthogranuloma, reportedly show adipophilin reactivity, but in contrast to the membranous vesicular pattern in sebaceous neoplasms, xanthomatous lesions show a more granular pattern. (
  • Therapy related myeloid neoplasms (t-MNs) constitute a distinct clinical syndrome including therapy related acute myeloid leukaemia (t-AML), myelodysplastic syndrome (t-MDS), and myelodysplastic/myeloproliferative neoplasm (t-MDS/MPN). (
  • Beginning at the age of 6 months, Myc His transgenic mice developed B-cell and plasma neoplasms, such as IgM + lymphoblastic B-cell lymphomas, Bcl-6 + diffuse large B-cell lymphomas, and CD138 + plasmacytomas, with an overall incidence of 68% by 21 months. (
  • Primary hepatobiliary neoplasms (PHN) are uncommon in cats, and originate in hepatocytes, intra- and extrahepatic bile ducts, mesenchymal cells, and cells of neuroendocrine origin. (
  • Pancreatic neuroendocrine neoplasms with a Ki-67 labeling index greater than 20% were reclassified in 2017 by the World Health Organization into well differentiated (WD) and poorly differentiated grad. (
  • We report the case of a 40-year-old woman that was diagnosed with a neuroendocrine neoplasm (NEN) of the rectum and multiple synchronous liver metastases ten years ago. (
  • This report represents the first case of an anti-Ri positive paraneoplastic brainstem encephalitis in a patient with exceptionally long course of a metastasized neuroendocrine rectum neoplasm. (
  • Plasma cell neoplasms are more common in middle-aged people and senior citizens, with males more at risk than females, notes the NCI. (
  • Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. (
  • These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia trachomatis, Neisseria gonorrhoeae, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 2. (
  • Conclusion: Inclusion of a single anti-TRBC1 antibody into a diagnostic T-cell flow cytometry panel facilitates the rapid identification of T-cell neoplasms, in addition to small monotypic CD8-positive subsets of uncertain significance. (
  • Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. (
  • In human samples, the expression of TFF1 was specifically observed in pancreatic intraepithelial neoplasm (PanIN), but was frequently lost in the invasive component of pancreatic ductal adenocarcinoma (PDAC). (
  • Autoimmune encephalitis presents an immune response against neuronal autoantigens with production of antibodies 6 . (
  • The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb Display™ technology for antibody discovery, its SMAC-Technology™ for site-specific payload conjugation of toxins to antibodies and a novel highly effective and immune-stimulatory anthracycline-based toxin platform. (
  • SOTIO's robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). (
  • The autoantigens are organ and cell-specific, and in some cases surgical removal of the neoplasm has resulted in amelioration of immune-mediated paraneoplasia.2,14-18 Gammaglobulin treatment is reported to have beneficial results in some through processes that include anti-idiotype immunomodulation.19 Plasmapheresis and immuno- suppression may provide symptomatic relief in others,3,6,15,20 but no single immunomodulation is universally successful. (
  • The description of an antibody specific for one of two mutually exclusive T-cell receptor (TCR) β-chain constant regions (TRBC1) provide an opportunity to facilitate the detection of clonal TCRαβ T-cells based on TRBC-restriction. (
  • Dahiyat said that the partial clinical hold will have no effect on Xencor's ongoing Phase I studies evaluating its other CD3 bispecific antibodies. (
  • Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. (
  • Examples of such antibodies will be discussed here with emphasis on those used as probes for molecular imaging and other clinical trials. (
  • Successful examples include rituximab, approved by the FDA since 1997, an anti-CD20 chimeric antibody that become an integral component of many treatment strategies for non-Hodgkin's lymphoma [ 2 ], and OKT3, an anti-CD3 that is used to reduce graft rejection [ 3 ]. (
  • However, an understanding of the ever growing number of commercially available antibodies and their limitations can maximize the pathologist's ability to make a definitive diagnosis. (
  • We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody-drug conjugates (ADCs) exhibited subnanomolar IC 50 values against AML cell lines in vitro . (